The PhilosoPhi34 (EudraCT: 2012-005062-34) study aimed to verify the clearance of BM CD34+/lin- Ph+ cells in CML patients after 3, 6 and 12 months of nilotinib treatment. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.